Cell envelope constituents and the multifaceted nature of Mycobacterium avium pathogenicity and drug resistance.
Rastogi
N
N
Laboratoire de la Tuberculose et des Mycobactéries, Institut Pasteur, Pointe à Pitre, Guadeloupe, French West Indies.
Barrow
W W
WW
D000942:Antigens, Bacterial / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology; D002462:Cell Membrane / Q000648:ultrastructure; D015232:Dinoprostone / Q000096:biosynthesis; D004352:Drug Resistance, Microbial; D006017:Glycolipids / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology; D006020:Glycopeptides / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D015269:Mycobacterium avium Complex / Q000276:immunology / Q000378:metabolism / Q000472:pathogenicity / Q000648:ultrastructure*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000942:Antigens, Bacterial; D006017:Glycolipids; D006020:Glycopeptides; D014409:Tumor Necrosis Factor-alpha; D015232:Dinoprostone